Press release
Dry Age-Related Macular Degeneration Market Projected to Grow at 7.9% CAGR, Reaching USD 19.8 Billion by 2034
Dry Age-Related Macular Degeneration Market
Dry Age-Related Macular Degeneration (Dry AMD) is a progressive eye disorder that damages the macula, leading to central vision loss. Unlike the wet form of AMD, dry AMD progresses slowly but is more common, accounting for 85-90% of all AMD cases. It is most prevalent in people aged 60 and above, making it a major cause of irreversible vision loss among the elderly.
Currently, treatment options for dry AMD are limited to nutritional supplements, lifestyle modifications, and supportive care. However, recent advancements in complement inhibitors, regenerative therapies, and gene therapy are reshaping the market outlook. With global aging trends, increased diagnostic adoption, and expanding research, the Dry AMD Market is set for significant growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72254
Market Overview
• Market Size (2024): Estimated at USD 9.2 billion
• Forecast (2034): Expected to reach USD 19.8 billion
• CAGR (2024-2034): Projected at 7.9%
Key Growth Drivers
• Rising aging population worldwide, especially in developed countries.
• Growing awareness and early diagnosis through retinal imaging.
• Strong pipeline of complement inhibitors (e.g., targeting C3 and C5 pathways).
• Expanding focus of biotech firms on regenerative ophthalmology.
Key Challenges
• Lack of approved curative therapies for dry AMD.
• High cost of emerging biologics and gene therapies.
• Regional disparities in access to diagnostic and treatment infrastructure.
• Slow disease progression complicating clinical trial design.
Leading Players
Apellis Pharmaceuticals, Iveric Bio (Astellas), Genentech/Roche, Novartis, Regeneron, Alcon, Bayer, and device makers like ZEISS and Topcon in diagnostics.
Segmentation Analysis
By Treatment Type
• Nutritional Supplements (AREDS/AREDS2 formulations)
• Complement Inhibitors (C3, C5 pathway therapies)
• Regenerative & Stem Cell Therapies
• Gene Therapies (emerging)
• Supportive & Symptomatic Care (visual aids, rehabilitation)
By Disease Stage
• Early Dry AMD
• Intermediate Dry AMD
• Advanced Dry AMD (Geographic Atrophy)
By Distribution Channel
• Hospitals & Specialty Ophthalmology Clinics
• Retail & Online Pharmacies
• Academic & Research Institutes
By End User
• Elderly Patient Population
• Specialty Eye Care Providers
• Research Centers
Segmentation Summary
Nutritional supplements remain widely used, but the most significant growth is expected in complement inhibitors (e.g., pegcetacoplan, avacincaptad pegol) targeting geographic atrophy. Regenerative medicine and gene therapy represent long-term transformative opportunities.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72254/dry-amd-market
Regional Analysis
North America
• 2024 Market Size: USD 3.8 billion
• 2034 Forecast: USD 8.1 billion
• CAGR: 8.0%
The U.S. dominates with strong adoption of imaging diagnostics and early approvals of complement inhibitors.
Europe
• 2024 Market Size: USD 2.7 billion
• 2034 Forecast: USD 5.6 billion
• CAGR: 7.6%
Germany, France, and the U.K. lead, supported by aging demographics and expanding access to advanced biologics.
Asia-Pacific
• 2024 Market Size: USD 2.0 billion
• 2034 Forecast: USD 5.0 billion
• CAGR: 9.3%
China, Japan, and South Korea are driving growth with rapidly aging populations and increasing investments in ophthalmology research.
Middle East & Africa
• 2024 Market Size: USD 0.35 billion
• 2034 Forecast: USD 0.7 billion
• CAGR: 7.0%
Saudi Arabia and South Africa are expanding retinal care facilities, though access gaps remain.
Latin America
• 2024 Market Size: USD 0.35 billion
• 2034 Forecast: USD 0.8 billion
• CAGR: 7.4%
Brazil and Mexico lead the region, with improving awareness and adoption of nutritional therapies.
Regional Summary
North America and Europe dominate today, but Asia-Pacific shows the fastest growth, fueled by its rapidly aging population and increasing healthcare investment.
Market Dynamics
Key Growth Drivers
• Expanding elderly population globally.
• Breakthroughs in complement pathway inhibitors for geographic atrophy.
• Increasing adoption of retinal imaging diagnostics for early detection.
• Rising research investment in stem cell and gene therapy solutions.
Key Challenges
• Limited availability of curative therapies.
• High treatment costs limiting accessibility.
• Complex clinical trial designs due to slow disease progression.
• Uneven access to advanced ophthalmology infrastructure.
Latest Trends
• Launch of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) for geographic atrophy in the U.S.
• Growing research into gene therapies targeting retinal degeneration.
• Development of AI-driven diagnostic platforms for AMD screening.
• Expansion of combination approaches (e.g., complement inhibition + regenerative therapy).
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72254
Competitor Analysis
Key Companies
• Apellis Pharmaceuticals - Leading with pegcetacoplan (Syfovre).
• Iveric Bio (Astellas) - Developer of avacincaptad pegol (Izervay).
• Roche/Genentech - Strong pipeline in retinal disease biologics.
• Novartis & Regeneron - Expanding ophthalmology portfolios.
• Alcon - Surgical and diagnostic innovations.
• ZEISS & Topcon - Dominating retinal imaging and diagnostic devices.
Competitive Dynamics
The market is transitioning from supportive care to biologic-driven solutions, led by recent FDA approvals. Competition is intensifying as more companies invest in complement inhibitors and regenerative therapies, with partnerships between pharma and biotech accelerating innovation.
Conclusion
The Dry Age-Related Macular Degeneration Market is projected to grow from USD 9.2 billion in 2024 to USD 19.8 billion by 2034, at a CAGR of 7.9%.
Opportunities Ahead
• Expansion of complement inhibitors for geographic atrophy.
• Growth in Asia-Pacific fueled by rapid aging.
• Integration of AI-driven diagnostics into ophthalmology practices.
• Long-term potential in regenerative and gene therapies.
This report is also available in the following languages : Japanese (ドライAMD市場), Korean (건조 AMD 시장), Chinese (干燥的AMD市场), French (Marché AMD sec), German (Trockener AMD-Markt), and Italian (Mercato della degenerazione maculare secca), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72254
Our More Reports:
Familial Hypercholesterolemia Market
https://exactitudeconsultancy.com/reports/71988/familial-hypercholesterolemia-market
Diabetic Neuropathic Pain (DNP) Market
https://exactitudeconsultancy.com/reports/71986/diabetic-neuropathic-pain-dnp-market
Diabetic Kidney Disease (DKD) Market
https://exactitudeconsultancy.com/reports/71984/diabetic-kidney-disease-dkd-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-Related Macular Degeneration Market Projected to Grow at 7.9% CAGR, Reaching USD 19.8 Billion by 2034 here
News-ID: 4192337 • Views: …
More Releases from Exactitude Consultancy
Fuchs' Dystrophy Market Poised to Grow at 8.2% CAGR, Reaching USD 1.15 Billion b …
Introduction
Fuchs' endothelial corneal dystrophy (FECD), commonly known as Fuchs' dystrophy, is a progressive eye disease that affects the corneal endothelium-the innermost layer of the cornea responsible for maintaining corneal clarity. The disease leads to corneal swelling, vision distortion, glare, and eventual vision loss. It primarily affects individuals over the age of 50 and is one of the leading indications for corneal transplantation worldwide.
While corneal transplant (penetrating keratoplasty or endothelial keratoplasty)…
Choroideremia Market Set to Surge at 12.4% CAGR, Reaching USD 210 Million by 203 …
Introduction
Choroideremia is a rare, inherited X-linked retinal degenerative disease characterized by progressive vision loss, night blindness, and eventual blindness, typically in male patients.
Currently, no approved treatment exists to halt or reverse choroideremia progression. However, the emergence of gene therapies, stem cell therapies, and retinal implants is transforming the therapeutic outlook. With rising research investment, orphan drug designations, and growing patient advocacy, the Choroideremia Market is expected to expand significantly…
Childhood Atropine for Myopia Progression Market Poised to Grow at 9.9% CAGR, Re …
Introduction
Myopia, or nearsightedness, has reached epidemic proportions worldwide, with prevalence surging particularly in children. Without effective interventions, childhood myopia often progresses to high myopia, significantly raising the risk of retinal detachment, glaucoma, cataracts, and myopic macular degeneration later in life.
One of the most promising treatments for slowing myopia progression in children is low-dose atropine therapy. Clinical studies have demonstrated that low concentrations of atropine (0.01% to 0.05%) are effective in…
Central Serous Chorioretinopathy Market Forecast to Grow at 7.8% CAGR, Reaching …
Introduction
Central Serous Chorioretinopathy (CSC) is a retinal disorder characterized by the accumulation of fluid under the retina, leading to distorted or blurred vision. While acute cases often resolve spontaneously, chronic CSC can result in permanent visual impairment due to retinal pigment epithelium damage. The condition primarily affects men between the ages of 30 and 50 and is associated with risk factors such as corticosteroid use, stress, hypertension, and Type A…
More Releases for AMD
Onlive Server Brings AI-Powered AMD Dedicated Servers
We are all aware of how useful, and sometimes even crucial, proper hosting services can be for a business. That is why Onlive Server is providing this new option with the newly recommended AI-powered AMD Dedicated Server Hosting[https://onliveserver.com/amd-dedicated-server-hosting/]. Furthermore, these servers are powered by AMD technology and do superbly in servicing the tremendous demand of agile business workloads with modern AI computations, big data, and other emerging technologies.
AI-powered solutions are…
Age-Related Macular Degeneration Market To Expand, Fuelled By Innovations In Dry …
The Age-related Macular Degeneration Market (AMD) is poised for significant growth over the coming years, with projections indicating a compound annual growth rate (CAGR) of 6.2%, leading to an estimated market value of $20 billion by the end of the forecast period. This robust expansion is driven by several critical factors, including the rising prevalence of eye diseases, advancements in medical technology, and an aging population that is increasingly susceptible…
AMD Workstations Market | BIZON, BOXX Technologies, Broadberry, Dell
The global amd workstations market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the amd workstations market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Airway Management Products (AMD) Market 2021 | Detailed Report
Airway Management Products (AMD) Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5262437
The report provides a comprehensive analysis of company profiles listed below:
- Medtronic
- Teleflex
- Ambu
- Smiths Medical
- Intersurgical
- Becton Dickinson
- Armstrong Medical
- Medline Industries
Airway Management Products…
Age-Related Macular Degeneration (AMD) Market Report 2018: Segmentation by Type …
Global Age-Related Macular Degeneration (AMD) market research report provides company profile for F. Hoffmann-La Roche AG, Regeneron Pharmaceutical Inc., Novartis AG, Bayer AG, Santen Pharmaceuticals and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc.…
Global Microprocessor Market 2018 - Intel, Qualcomm, Apple, AMD
Apex Market Reports, recently published a detailed market research study focused on the “Microprocessor Market” across the global, regional and country level. The report provides 360° analysis of “Microprocessor Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Microprocessor on the basis of…
